An open, randomized, multicentre study comparing the use of low-dose ceftazidime or cefotaxime, both in combination with netilmicin, in febrile neutropenic patients

Journal of Antimicrobial Chemotherapy

Volumn 44, Issue 3, 1999, Pages 367-376

  Hoffken G ^a   Pasold, R ^b   Pfluger K H ^c   Finke, J ^d   Fauser, A A ^e   Szelenyi, H ^a   Wagner, J ^f   Fauser, A ^g   Grueisen A ^g   Hofeler H ^g   Petrasch, S ^g   Respondek, M ^g   Thiel, E ^g  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b KLINIKUM ERNST VON BERGMANN   (Germany)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

^e Klin Knochenmarkstransplantation H   (Germany)

^f Institut für Infektionsmedizin   (Germany)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CEFOTAXIME; CEFTAZIDIME; FLUCLOXACILLIN; MACROLIDE; METRONIDAZOLE; NETILMICIN; RIFAMPICIN; TEICOPLANIN; VANCOMYCIN;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; BACTERIUM ISOLATION; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE DURATION; DRUG EFFICACY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; GERMANY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; IMMUNE DEFICIENCY; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PYREXIA IDIOPATHICA; RANDOMIZED CONTROLLED TRIAL; RASH; SUPERINFECTION; TREATMENT FAILURE; VOMITING;

EID: 0344131956     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/44.3.367     Document Type: Article

References (34)

1. Hughes, W.T., Armstrong, D., Bodey, G. P., Feld, R., Mandell, G. L., Meyers, J. D. et al. (1990). Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Journal of Infectious Diseases 161, 381-96.
2. Hughes, W. T., Armstrong, D., Bodey, G. P., Brown, A. E., Edwards, J. E., Feld, R. et al. (1997). 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clinical Infectious Diseases 25, 551-73.
3. Lüthy, R., Blaser, J. Bonetti, A., Simmen, H., Wise, R. & Siegenthaler, W. (1981). Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime. Antimicrobial Agents and Chemotherapy 20, 567-75.
4. Hyatt, J. M., McKinnon, P. S., Zimmer, G. S. & Schentag, J. J. (1995). The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clinical Pharmacokinetics 28, 143-60.
5. Sculier, J. P. & Klastersky, J. (1984). Significance of serum bactericidal activity in Gram-negative bacillary bacteraemia in patients with and without granulocytopenia. American Journal of Medicine 76, 429-35.
6. lmmunocompromised Host Society. (1990). The design, analysis and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel. Journal of Infectious Diseases 161, 397-401.
7. Balows, A. (1991). Manual of Clinical Microbiology, 5th edn. American Society for Microbiology, Washington, DC.
8. Deutsches Institut für Normierung e.V. (DIN). (1990) Methoden zur Empfindlichkeitsprüfung von bakteriellen Krankheitserregern (auβer Mycobakterien) gegen Chemotherap. DIN 58940. Teil 8, Beuth-Verlag, Berlin.
9. Brown, A. E., Kiehn, T. E. & Armstrong, D. (1995). Bacterial resistance in the patient with neoplastic disease. Infectious Diseases in Clinical Practice 3, Suppl. 4, 136-44.
10. Barza, M., Ioannidis, J. P., Cappelleri, J. C. & Lau, J. (1996). Single or multiple daily doses of aminoglycosides: a meta-analysis. British Medical Journal 312, 338-45.
11. Moore, R. D., Lietman, P. S. & Smith, C. R. (1987). Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. Journal of Infectious Diseases 155, 93-9.
12. Blaser, J., Stone, B. B., Groner, M. C. & Zinner, S. H. (1987). Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrobial Agents and Chemotherapy 31, 1054-60.
13. Kapusnik, J. E., Hackbarth, C. J., Chambers, H. F., Carpenter, T. & Sande, M. A. (1988). Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental Pseudomonas pneumonia. Journal of Infectious Diseases 158, 7-12.
14. Preston, S. L. & Briceland, L. L. (1995). Single daily dosing of aminoglycosides. Pharmacotherapy 15, 297-316.
15. Craig, W. A. & Ebert, S. C. (1990). Killing and regrowth of bacteria in vitro: a review, Scandinavian Journal of Infectious Diseases. Supplementum 74, 63-70.
16. Schentag, J. J., Smith, I. L., Swanson, D. J., DeAngelis, C., Fracasso, J. E., Vari, A. et al. (1984). Role for dual individualization with cefmenoxime. American Journal of Medicine 77, Suppl. 6A, 43-50.
17. Nishida, M., Murakawa, T., Kamimura, T. & Okada, N. (1978). Bactericidal activity of cephalosporins in an in vitro model simulating serum levels. Antimicrobial Agents and Chemotherapy 14, 6-12.
18. Paradis, D., Vallée, F., Allard, S., Bisson, C., Daviau, N., Drapeau, C. et al. (1992). Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin. Antimicrobial Agents and Chemotherapy 36, 2085-92.
19. Vogelman, B., Gudmundsson, S., Leggett, J., Turnidge, J., Ebert, S. & Craig, W. A. (1988). Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. Journal of Infectious Diseases 158, 831-47.
20. Drusano, G. L. & Goldstein, F. W. (1996). Relevance of the Alexander Project: pharmacodynamic considerations. Journal of Antimicrobial Chemotherapy 38, Suppl. A, 141-54.
21. Joshi, J. H., Schimpft, S. C.,Tenney, J. H., Newman, K. A. & de Jongh, C. A. (1984). Can antibacterial therapy be discontinued in persistently granulocytopenic cancer patients? American Journal of Medicine 76, 450-7.
22. Bash, R. O., Katz, J. A., Cash, J. V. & Buchanan, G. R. (1994). Safety and cost effectiveness of early hospital discharge of lower risk children with cancer admitted for fever and neutropenia. Cancer 74, 189-96.
23. Lau, R. C., Doyle, J. J., Freedman, M. H., King, S. M. & Richardson, S. E. (1994). Early discharge of pediatric febrile neutropenic cancer patients by substitution of oral for intravenous antibiotics. Pediatric Hematology and Oncology 11, 417-21.
24. Talcott, J. A., Whalen, A., Clark, J., Rieker, P. P. & Finberg, R. (1994). Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. Journal of Clinical Oncology 12, 107-14.
25. Cometta, A., Calandra, T., Gaya, H., Zinner, S. H., de Bock, R., Del Favero, A. et al. (1996). Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrobial Agents and Chemotherapy 40, 1108-15.
26. Laszlo, D., Bacci, S., Bosi, A., Fanci, R., Guidi, S. Saccardi, R. et al. (1997). Randomized trial comparing netilmicin plus imipenem-cilastatin versus netilmicin plus ceftazidime as empiric therapy for febrile neutropenic bone marrow transplant recipients. Journal of Chemotherapy 9, 95-101.
27. Rolston, K. V. I., Berkey, P., Bodey, G. P., Anaissie, E. J., Khardori, N. M., Joshi, J. H. et al. (1992). A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Archives of Internal Medicine 152, 283-91.
28. Gibson, J., Johnson, L., Snowdon, L., Joshua, D., Young, G., MacLeod, C. et al. (1994). A randomized dosage study of ceftazidime with single daily tobramycin for the empirical management of febrile neutropenia in patients with hematological diseases. International Journal of Hematology 60, 119-27.
29. Marie, J. P., Pico, J. L., Chiche, D., Fitoussi, F., Delmer, A., Baume, D. et al. (1988). Protocole d'antibiothérapie utilisant la ceftazidime á la dose de 3 g/jour seule ou en association avec la vancomycine ou l'amikacine. Lors des episodes febriles chez le neutropenique. Presse Médicale 17, 1968-70.
30. Marie, J. P., Pico, J., Lapierre, V., Maulard, C., Pappo, M., Chiche, D. et al. (1991). Traitement empirique des épisodes fébriles survenant chez les patients cancéreux présentant une neutropénie prolongée: essai comparatif ceftazidime seule, ceftazidime + amikacine et ceftazidime + vancomycine. Médicale Maladies Infectieuses 21, 386-8.
31. Klastersky, J., Glauser, M. P., Schimpff, S. C., Zinner, S. H. & Gaya, H. (1986). Prospective randomized comparison of three antibiotic regimens for empirical therapy of suspected bacteremic infection in febrile granulocytopenic patients. Antimicrobial Agents and Chemotherapy 29, 263-70.
32. Böhme, A., Just-Nübling, G., Bergmann, L., Shah, P. M., Stille, W. & Hoelzer, D. (1995). A randomized study of imipenem compared to cefotaxime plus piperacillin as initial therapy of infections in granulocytopenic patients. Infection 23, 349-55.
33. De Pauw, B. E., Deresinski, S. C., Feld, R., Lane-Allman, E. F. & Donnelly, J. P. (1994). Ceftazidime compared with piperacillin and tobramycin (or the empiric treatment of fever in neutropenic patients with cancer. A multicentre randomized trial. The Intercontinental Antimicrobial Study Group. Annals of Internal Medicine 120, 834-44.
34. De Pauw, B. E. (1990). Treatment of infection in neutropenia. Current Opinion in Infectious Diseases 3, 197-202.